HeartBeam Sets Q3 2026 Earnings Call, Highlighting Cardiac Tech Progress
Found this article helpful?
Share it with your network and spread the knowledge!

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has scheduled a conference call for Thursday, November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2026. The call will also provide updates on recent achievements, including results from the ALIGN-ACS pilot study, and upcoming milestones for the company’s Heart Attack Detection program.
The timing of this announcement is significant for Texas’s business and healthcare landscape. HeartBeam, which is developing the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, represents the kind of innovative medical technology that can drive economic growth and improve patient outcomes. The company’s technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining cardiac health management.
HeartBeam’s progress is notable: its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. These regulatory milestones position HeartBeam to potentially capture a significant share of the cardiac monitoring market, which could have ripple effects across Texas’s medical device and healthcare sectors. The ALIGN-ACS pilot study results, to be discussed on the call, may offer further validation of the technology’s clinical utility, which is critical for adoption and reimbursement.
For investors and industry observers, the upcoming call offers a window into HeartBeam’s financial health and strategic direction. Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the call, followed by a question-and-answer session. Participants can access the conference by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally using conference code 13763268. A webcast and accompanying presentation will be available, with a telephone replay accessible approximately three hours after the call through November 26, 2026.
The full press release is available at https://ibn.fm/QEwx4. For more information on HeartBeam, visit its HeartBeam (NASDAQ: BEAT) profile. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Details on the intended use of its technology can be found at https://www.heartbeam.com/indications.
This announcement is distributed through MissionIR, a specialized communications platform within the Dynamic Brand Portfolio at IBN. IBN provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For full terms of use and disclaimers, see https://www.MissionIR.com/Disclaimer.
